Hanh Bui, MD
Cardiovascular Disease · Vista, CANPI 1275519175
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 44 manufacturers reported payments, led by Kestra Medical Technology Services, Inc. at 33.6% of the total. 2025 is the largest year on record at $12,236, 5.3 times the $2,299 reported in 2019. Among cardiovascular disease clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 517 payments — averaging $55.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kestra Medical Technology Services, Inc.$10K
- Novartis$4K
- Janssen Research & Development, LLC$3K
- Boston Scientific$2K
- Abbott$2K
- Bayer$1K
- plus $8K from 38 others
Across 221 payments — averaging $12,135 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1M
- Janssen Research & Development, LLC$710K
- Merck$259K
- Astrazeneca UK Limited$200K
- Bayer$196K
- AstraZeneca$157K
- plus $122K from 6 others
What the payments were for
- Consulting fees$11,32540%
- Travel & lodging$3,63313%
- Food & beverage$13,52147%
- Education$1651%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Assure WCD$9,332
- LEQVIO$1,234
- Allure CRT Pacemaker$1,200
- (7999) SRC Undivided$475
- LUX-Dx Insertable Cardiac Monitor$278
- Rivacor 7 DR-T$228
- Watchman$222
- CoreValve Evolut$144
- Quadra Assura CRT Defibrillator$139
- SQ RX PULSE GENERATOR$137
- Carnation Ambulatory Monitor$125
- ZEPBOUND$124
- Restrata Wound Matrix$121
- Acticor 7 VR-T DX$116
- Edora 8 DR-T$116
- BioMonitor$116
- GENERAL - THERAPIES$108
- Advisa$102
How this compares
$28,645 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 716 | $802,817 |
| EntrestoSacubitril/Valsartan | 272 | $312,923 |
| OzempicSemaglutide | 221 | $266,449 |
| JardianceEmpagliflozin | 161 | $134,190 |
| XareltoRivaroxaban | 115 | $114,526 |
| MounjaroTirzepatide | 55 | $60,847 |
| Repatha SureclickEvolocumab | 41 | $45,661 |
| TrulicityDulaglutide | 39 | $39,846 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $36,742 |
| Repatha SyringeEvolocumab | 20 | $22,012 |
| MultaqDronedarone Hcl | 16 | $22,009 |
| FarxigaDapagliflozin Propanediol | 20 | $21,282 |
| JanuviaSitagliptin Phosphate | 24 | $17,918 |
| BrilintaTicagrelor | 29 | $17,279 |
| VerquvoVericiguat | 18 | $12,731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $554 | $802,817716 claims |
| NovartisEntresto | $3,794 | $312,923272 claims |
| Novo NordiskOzempic | $234 | $266,449221 claims |
| Boehringer IngelheimJardiance | $468 | $134,190161 claims |
| Johnson & JohnsonXarelto | $419 | $114,526115 claims |
| Lilly USA, LLCMounjaro, Trulicity | $312 | $100,69394 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $390 | $48,04150 claims |
| AstraZenecaFarxiga, Brilinta | $158 | $38,56149 claims |
| MerckJanuvia, Verquvo | $671 | $30,64842 claims |
| Sanofi-aventis U.S. LLCMultaq | $300 | $22,00916 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $28 | $5,89614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Vista
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
- Thomas SmithSacramento$942K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.